Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant African swine fever virus Uncharacterized protein H124R (Ken-127) CSB-YP317099AEB
CSB-EP317099AEB
CSB-BP317099AEB
CSB-MP317099AEB
CSB-EP317099AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Structural protein A137R (Ken-054) CSB-YP317100AEB
CSB-EP317100AEB
CSB-BP317100AEB
CSB-MP317100AEB
CSB-EP317100AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein K145R (War-061) CSB-YP317101AEI
CSB-EP317101AEI
CSB-BP317101AEI
CSB-MP317101AEI
CSB-EP317101AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein EP152R (Pret-068) CSB-YP317102AYG
CSB-EP317102AYG
CSB-BP317102AYG
CSB-MP317102AYG
CSB-EP317102AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein F165R (Pret-058), partial CSB-YP317103AYG1
CSB-EP317103AYG1
CSB-BP317103AYG1
CSB-MP317103AYG1
CSB-EP317103AYG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein H171R (Pret-126) CSB-YP317104AYG
CSB-EP317104AYG
CSB-BP317104AYG
CSB-MP317104AYG
CSB-EP317104AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein E184L (Ken-137) CSB-YP317105AEB
CSB-EP317105AEB
CSB-BP317105AEB
CSB-MP317105AEB
CSB-EP317105AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Late protein I196L (War-156) CSB-YP317106AEI
CSB-EP317106AEI
CSB-BP317106AEI
CSB-MP317106AEI
CSB-EP317106AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Late protein I226R (Ken-149) CSB-YP317107AEB
CSB-EP317107AEB
CSB-BP317107AEB
CSB-MP317107AEB
CSB-EP317107AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein H233R (War-128) CSB-YP317108AEI
CSB-EP317108AEI
CSB-BP317108AEI
CSB-MP317108AEI
CSB-EP317108AEI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein M1249L (Ken-072), partial CSB-YP317109AEB
CSB-EP317109AEB
CSB-BP317109AEB
CSB-MP317109AEB
CSB-EP317109AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Transmembrane protein C257L (Pret-078), partial CSB-YP317110AYG1
CSB-EP317110AYG1
CSB-BP317110AYG1
CSB-MP317110AYG1
CSB-EP317110AYG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein CP312R (Ken-108) CSB-YP317111AEB
CSB-EP317111AEB
CSB-BP317111AEB
CSB-MP317111AEB
CSB-EP317111AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Transmembrane protein I329L (Ken-153), partial CSB-YP317112AEB
CSB-EP317112AEB
CSB-BP317112AEB
CSB-MP317112AEB
CSB-EP317112AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus ERCC4 domain-containing protein EP364R (Ken-071) CSB-YP317113AEB
CSB-EP317113AEB
CSB-BP317113AEB
CSB-MP317113AEB
CSB-EP317113AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein B407L (Ken-096) CSB-YP317114AEB
CSB-EP317114AEB
CSB-BP317114AEB
CSB-MP317114AEB
CSB-EP317114AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein K421R (Pret-064) CSB-YP317115AYG
CSB-EP317115AYG
CSB-BP317115AYG
CSB-MP317115AYG
CSB-EP317115AYG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein B475L (Ken-089), partial CSB-YP317116AEB
CSB-EP317116AEB
CSB-BP317116AEB
CSB-MP317116AEB
CSB-EP317116AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein C62L (Ken-082) CSB-YP317117AEB
CSB-EP317117AEB
CSB-BP317117AEB
CSB-MP317117AEB
CSB-EP317117AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant African swine fever virus Uncharacterized protein DP63R (Ken-160) CSB-YP317118AEB
CSB-EP317118AEB
CSB-BP317118AEB
CSB-MP317118AEB
CSB-EP317118AEB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>